Pulmonary arterial hypertension preceding idiopathic pulmonary fibrosis in a BMPR2 mutation positive patient

European Respiratory Review

Volumn 23, Issue 131, 2014, Pages 147-149

  Raamsteeboers, Aniek J ^a   Bogaard, Harm Jan ^a   Noordegraaf, Anton Vonk ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; DIURETIC AGENT; SILDENAFIL;

AGED; BRONCHIECTASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; GENE MUTATION; HEART CATHETERIZATION; HUMAN; LETTER; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; PULMONARY HYPERTENSION; VERY ELDERLY;

AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; MUTATION; PHENOTYPE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84895432663     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00005513     Document Type: Letter

References (10)

1. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc. and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
2. Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur Respir J 2011; 37: 743-746.
3. Wells AU. Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Respir Rev 2013; 22: 158-162.
4. Cahill E, Costello CM, Rowan SC, et al. Gremlin plays a key role in the pathogenesis of pulmonary hypertension. Circulation 2012; 125: 920-930.
5. Costello CM, Howell K, Cahill E, et al. Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension. Am J Physiol Lung CellMol Physiol 2008; 295: L272-L284.
6. Myllärniemi M, Lindholm P, Ryynänen MJ, et al. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 321-329.
7. Koli K, Myllärniemi M, Vuorinen K, et al. Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol 2006; 169: 61-71.
8. Myllärniemi M, Vuorinen K, Pulkkinen V, et al. Gremlin localization and expression levels partially differentiate idiopathic interstitial pneumonia severity and subtype. J Pathol 2008; 214: 456-463.
9. Durrington HJ, Morrell NW. What we know and what we would like to know about genetics and pulmonary arterial hypertension. Int J Clin Pract Suppl 2009; 161: 11-16.
10. Costello CM, Cahill E, Martin F, et al. Role of gremlin in the lung: development and disease. Am J Respir Cell Mol Biol 2010; 42: 517-523.